These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 23795969)

  • 1. Protein crystallography and fragment-based drug design.
    Caliandro R; Belviso DB; Aresta BM; de Candia M; Altomare CD
    Future Med Chem; 2013 Jun; 5(10):1121-40. PubMed ID: 23795969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography.
    Amano Y; Yamaguchi T; Tanabe E
    Bioorg Med Chem; 2014 Apr; 22(8):2427-34. PubMed ID: 24656800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-based lead discovery using X-ray crystallography.
    Hartshorn MJ; Murray CW; Cleasby A; Frederickson M; Tickle IJ; Jhoti H
    J Med Chem; 2005 Jan; 48(2):403-13. PubMed ID: 15658854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electron density guided fragment-based drug design--a lead generation example.
    Abad MC; Gibbs AC; Zhang X
    Methods Enzymol; 2011; 493():487-508. PubMed ID: 21371603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput X-ray crystallography for drug discovery.
    Blundell TL; Patel S
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. E-novo: an automated workflow for efficient structure-based lead optimization.
    Pearce BC; Langley DR; Kang J; Huang H; Kulkarni A
    J Chem Inf Model; 2009 Jul; 49(7):1797-809. PubMed ID: 19552372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based screening using X-ray crystallography and NMR spectroscopy.
    Jhoti H; Cleasby A; Verdonk M; Williams G
    Curr Opin Chem Biol; 2007 Oct; 11(5):485-93. PubMed ID: 17851109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico fragment-based drug design.
    Konteatis ZD
    Expert Opin Drug Discov; 2010 Nov; 5(11):1047-65. PubMed ID: 22827744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locating and characterizing binding sites on proteins.
    Mattos C; Ringe D
    Nat Biotechnol; 1996 May; 14(5):595-9. PubMed ID: 9630949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicinal chemistry inspired fragment-based drug discovery.
    Lanter J; Zhang X; Sui Z
    Methods Enzymol; 2011; 493():421-45. PubMed ID: 21371600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors.
    Drinkwater N; Vu H; Lovell KM; Criscione KR; Collins BM; Prisinzano TE; Poulsen SA; McLeish MJ; Grunewald GL; Martin JL
    Biochem J; 2010 Oct; 431(1):51-61. PubMed ID: 20642456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated protein-ligand crystallography for structure-based drug design.
    Mooij WT; Hartshorn MJ; Tickle IJ; Sharff AJ; Verdonk ML; Jhoti H
    ChemMedChem; 2006 Aug; 1(8):827-38. PubMed ID: 16902937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand mapping on protein surfaces by the 3D-RISM theory: toward computational fragment-based drug design.
    Imai T; Oda K; Kovalenko A; Hirata F; Kidera A
    J Am Chem Soc; 2009 Sep; 131(34):12430-40. PubMed ID: 19655800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery.
    Winter A; Higueruelo AP; Marsh M; Sigurdardottir A; Pitt WR; Blundell TL
    Q Rev Biophys; 2012 Nov; 45(4):383-426. PubMed ID: 22971516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions.
    Deng Z; Chuaqui C; Singh J
    J Med Chem; 2004 Jan; 47(2):337-44. PubMed ID: 14711306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel approach to local similarity of protein binding sites substantially improves computational drug design results.
    Ramensky V; Sobol A; Zaitseva N; Rubinov A; Zosimov V
    Proteins; 2007 Nov; 69(2):349-57. PubMed ID: 17623865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CORES: an automated method for generating three-dimensional models of protein/ligand complexes.
    Hare BJ; Walters WP; Caron PR; Bemis GW
    J Med Chem; 2004 Sep; 47(19):4731-40. PubMed ID: 15341488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational approach to de novo discovery of fragment binding for novel protein states.
    Konteatis ZD; Klon AE; Zou J; Meshkat S
    Methods Enzymol; 2011; 493():357-80. PubMed ID: 21371598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.